Kim Myung-sook named Novartis's Sebivo EGM leader

Published: 2006-12-21 06:57:00

Updated: 2006-12-21 06:57:00

Novartis Korea said Kim Myung-sook, 37, a team leader of Novartis Korea' infection unit, was named a global crew leader (Head Center of Exellence) of Sebivo (telbivudine), a new hepatitis B virus (HBV) nucleoside analog polymerase inhibitor, in the emerging growth market (EGM).

Her EGM marketi...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK